Burlington, MANCT04408625Now EnrollingIRB Ready

Frontotemporal Dementia Clinical Trial in Burlington, MA

Access cutting-edge frontotemporal dementia treatment through this clinical trial at a research site in Burlington. Study-provided care at no cost to qualified participants.

Sponsored by Prevail Therapeutics

Quick Self-Assessment

See if you qualify for this Burlington location

Preparing your pre-screening questions...

Expert Care in Burlington

Access frontotemporal dementia specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related frontotemporal dementia treatment provided free

Apply for This Burlington Location

Check if you qualify for this frontotemporal dementia clinical trial in Burlington, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Burlington

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Burlington site if eligible
  4. 4Begin participation

About This Frontotemporal Dementia Study in Burlington

Study J4B-MC-OKAA is a Phase 1/2, multi-center, open-label ascending dose, first-in-human study that will evaluate the safety and effect of intra-cisternal LY3884963 administration on progranulin protein (PGRN) levels in patients with frontotemporal dementia with progranulin mutations (FTD-GRN). Two escalating dose (low dose and medium dose) cohorts are planned, as well as one bridging cohort which will allocate patients to receive either low or medium dose. The duration of the study is 5 years.

Sponsor: Prevail Therapeutics

Who Can Participate

Inclusion Criteria

Men or women aged 30 to 85 years (inclusive), at the time of informed consent.
Body weight range of ≥40 kg (88 lbs) to ≤110 kg (242 lb) and a BMI of 18 to 34 kg/m2.
Has symptomatic frontotemporal dementia (FTD), including mild behavioral, cognitive, motor or language impairment per Investigator's assessment (behavioral-variant FTD, primary progressive aphasia-FTD, FTD with corticobasal syndrome, or a combination of syndromes are allowed for enrollment).
Score ≥0.5 and ≤15 on CDR plus NACC FTLD sum of boxes.
Stable use of background medications at least 8 weeks prior to LY3884963 dosing.
Carrier of a pathogenic progranulin gene (GRN) mutation.
Negative screening test for Mycobacterium tuberculosis (MTB) or documented negative MTB test within 1year prior to screening.
Age- and gender-appropriate cancer screenings are up-to-date and completed.
Patient and/or patient's legally authorized representative has the ability to understand the purpose and ris

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Burlington?

Yes, this clinical trial (NCT04408625) has an active research site in Burlington, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Frontotemporal Dementia Treatment Options in Burlington, MA

If you're searching for frontotemporal dementia treatment options in Burlington, MA, this clinical trial (NCT04408625) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Burlington research site is actively enrolling participants for this clinical trial. You'll receive care from experienced frontotemporal dementia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all frontotemporal dementia clinical trials near you to find additional studies recruiting in your area.

More Alzheimers Disease Trials in Burlington, MA

See all alzheimers disease clinical trials recruiting in Burlington — not just this study.

Browse Alzheimers Disease Trials in Burlington →

Browse More Trials by Condition

Alzheimers Disease TrialsRheumatoid Arthritis TrialsMyalgic Encephalomyelitis TrialsAll Conditions →

Ready to Join in Burlington?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Burlington, MA